

Readability of published vs artificial intelligence-generated plain-language summaries



Shobana Ganesan, Nilima Vyas, Swapna Ganduri*, Charvin D'souza and Namita Bose Cactus Life Sciences, Cactus Communications, Mumbai, India


*Presenting author

07

BACKGROUND

- Plain-language summaries (PLS), written in layman language, aim to make the results of biomedical research more accessible to a wide audience.^{1,2} However, writing scientific content in simple, non-technical language is often a challenge for authors³
- Generative artificial intelligence (GenAI) may be particularly useful in developing PLS owing to its ability to convert complex content into easily understandable language.
 GenAI outputs can be further enhanced and refined by using well-designed, specific prompts
- The objectives of our study were to
 - compare the readability of published vs corresponding GenAl-generated PLS
 - gather insights on PLS development using GenAl from medical publication professionals

METHODS



^aThe Flesch-Kincaid readability index comprises a reading ease score and a grade level score. Reading ease score is measured on a scale of 1 to 100, with higher scores indicative of better readability; grade level, which is reflective of the US grade level of education required to understand the assessed text, is measured on a scale of 0 to 17+; the higher the grade level, the more complex is the text.


RESULTS

Availability of PLS in medical literature




^aWord count range: 18–846 words.

Top five journals with published PLS^a



^aPercentages were calculated considering N=211 publications with an accompanying PLS

Readability of published vs GenAI PLS




• None of the published PLS met the recommended reading age of 12 years (grade level 6), whereas three GenAl PLS met the recommended reading age/grade level⁴

No meaning changes were observed in the GenAl PLS compared with the published PLS.

Survey results (N=65)

>50 words



Opinions on GenAl use in PLS development

- 66 Using AI such as ChatGPT to write publication PLS is limited due to the confidential nature of the content
 - In general, we cannot use AI for plain language summaries because inputting the data into a publicly available AI breaches confidentiality and could be considered prior publication that would prevent presentation of the data at a scientific congress or in a medical journal
 - 66 Al fundamental learning process puts proprietary information at risk and has a long way to go before it can be used in this setting
 - We are working with a proprietary Al.


 I anticipate good 1st drafts of PLS from this

 in the next year

CONCLUSIONS







Barriers to implementation of GenAl in PLS development, such as data confidentiality concerns, need to be overcome before considering its widespread use in medical publications

FUTURE DIRECTIONS

- GenAl tools hold promise in the development of plain-language materials that can improve the accessibility of biomedical research
- Specifying the desired age criteria/grade level in GenAl prompts might help generate outputs consistent with the recommended guidelines
- Use of GenAI to create preliminary drafts of PLS can be an efficient alternative to developing de novo PLS; however, human involvement will be essential to review GenAI-generated PLS for scientific accuracy, tone, and completeness
- Developing in-house/proprietary GenAl tools or using paid versions of available GenAl tools might assist in PLS development without confidentiality breach issues


ACKNOWLEDGMENTS


The authors have nothing to disclose. The authors thank the survey respondents for their valuable insights; Nilanjana Sengupta, Sudharsan Dhanapal, and Sandesh Salvi (employees of Cactus Life Sciences) for poster design and layout support; and Aiman Lakdawala and Pearl Gomes (both employees of Cactus Life Sciences) for data QC and editorial support.

REFERENCES

1. Rosenberg A, et al. *Curr Med Res Opin*. 2021;37:2015–2016; **2.** Edgell C, Rosenberg A. *Curr Med Res Opin*. 2022;38:871–874; **3.** Kirkpatrick E, et al. *Res Involv Engagem*. 2017;3:17; **4.** Summaries of Clinical Trial Results for Laypersons. https://health.ec.europa.eu/system/files/2020-02/2017_01_26_summaries_of_ct_results_for_laypersons_0.pdf (Accessed 15 Mar 2024).







Presented at the 20th Annual Meeting of ISMPP, April 29–May 1, 2024, Washington, DC, USA.

